Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Liderman; France: Fonx, Oxiconazole; Germany: Myfungar, Oceral; Spain: Salongo.

North America

USA: Oxistat.

Latin America

Brazil: Micotin, Oceral, Oxiconazol, Oxipelle; Mexico: Myfungar, Oxistat.


Japan: Oxistat.

Drug combinations


Oxiconazole Nitrate: C~18~H~13~Cl~4~N~3~O HNO~3~. Mw: 492.14. (1) Ethanone, 1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)-, O-[(2,4-dichlorophenyl)methyl]oxime, (Z)-, mononitrate; (2) 2′,4′-Dichloro-2-imidazol-1-ylacetophenone (Z)-[O-(2,4-dichlorobenzyl)oxime], mononitrate. CAS-64211-46-7; CAS-64211-45-6 (oxiconazole)(1987).

Pharmacologic Category

Skin and Mucous Membrane Agents; Antifungals; Azoles. Topical Antifungal Agent. (ATC-Code: D01AC11; G01AF17).

Mechanism of action

Mechanism of action unknown. Presumably inhibits ergosterol synthesis, and so alters cellular membranes, resulting in increased membrane permeability, secondary metabolic effects, and growth inhibition. Usually fungistatic. May be fungicidal at high concentrations or against very susceptible organisms. Active in vitro against dermatophytes such as Epidermophyton floccosum, Microsporum audouinii, M. canis, M. gypseum, Trichophyton mentagrophytes, T. rubrum, T. tonsurans, and T. violaceum. Active in vitro against candida such as Candida albicans, C. glabrata (Torulopsis glabrata), C. guilliermondii, C. krusei, C. parapsilosis, and C. tropicalis; against other fungi such as Malassezia furfur (Pityrosporum orbiculare). Active in vitro against Aspergillus flavus, A. fumigatus, A. nidulans, A. niger, Cryptococcus neoformans, Epidermophyton floccosum, Exophiala werneckii, Petriellidium boydii, and Sporothrix schenkii, also against bacteria such as Actinomadura madurae, Corynebacterium minutissimum, Nocardia asteroides, N. brasiliensis, and Streptomyces somaliensis. Cross-resistance can occur among azole antifungals. Some C. albicans resistant to ketoconazole show cross-resistance to oxiconazole and other imidazole-derivative antifungals as well as to triazole derivatives. Some strains of M. furfur (Pityrosporum orbiculare) resistant to oxiconazole in vitro are cross-resistant to econazole.

Therapeutic use

Tinea pedis (athlete’s foot), tinea cruris (jock itch), tinea corporis (ringworm), and tinea (pityriasis) versicolor.

Pregnancy and lactiation implications

Teratogenic effects not observed in animals. There are no adequate studies in pregnant women. Enters breast milk (use caution).

Unlabeled use


Hypersensitivity to oxiconazole or any component of the formulation.

Warnings and precautions

Discontinue if sensitivity or irritation occurs. Topical use only. Avoid contact with eyes or vagina.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart